Milrinone

Brands

DEA Class; Rx

Common Brand Names; Lanoxin

  • Inotropic Agents; 
  • Phosphodiesterase Enzyme Inhibitors
Parenteral positive inotrope and vasodilator with phosphodiesterase inhibitor activity
Used for short-term treatment of acute heart failure
Minimal chronotropic activity
Indicated for the short-term treatment of acute heart failure and other low cardiac output states (e.g., cardiogenic shock, low cardiac output syndrome (LCOS) after cardiac surgery).
For the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
For the short-term treatment of low cardiac output during septic shock or postresuscitation stabilization.
For the treatment of persistent pulmonary hypertension of the newborn (PPHN) in patients with poor response to nitric oxide.

Hypersensitivity to milrinone and inamrinone

  • Ventricular arrhythmias
  • Supraventricular arrhythmia (4%)
  • Headache (3%)
  • Hypotension (3%)
  • Angina/chest pain (1%)
  • Abnormal liver function test results
  • Anaphylaxis
  • Atrial fibrillation
  • Bronchospasm
  • Hypokalemia
  • Injection-site reaction
  • Rash
  • Thrombocytopenia
  • Torsades de pointes
  • Tremor
  • Ventricular premature complex

Use caution in atrial fibrillation/flutter, hypertrophic subaortic stenosis, electrolyte abnormalities, hypotension, recent MI, severe aortic or pulmonic valvular disease, renal impairment

Severe aortic or pulmonic obstruction, acute phase after myocardial infarction (MI)

May increase risk of arrhythmias

Ensure that ventricular rate is controlled in atrial fibrillation/flutter before initiating therapy; may increase ventricular response rate

Concurrent use of disopyramide

Discontinue therapy if symptoms of hepatotoxicity (eg., increased LFTs) occur; monitor liver function

Monitor blood pressure/heart rate closely

Short-term use only

Pregnancy category: C

Lactation: Unknown whether drug is excreted into breast milk; use with caution; nursing is not priority in situations where milrinone is used

Adults

0.75 mcg/kg/minute continuous IV infusion.

Geriatric

0.75 mcg/kg/minute continuous IV infusion.

Adolescents

Safety and efficacy have not been established; however, up to 1 mcg/kg/minute continuous IV infusion has been used.

Children

Safety and efficacy have not been established; however, up to 1 mcg/kg/minute continuous IV infusion has been used.

Infants

Safety and efficacy have not been established; however, up to 1 mcg/kg/minute continuous IV infusion has been used.

Neonates

Safety and efficacy have not been established; however, up to 1 mcg/kg/minute continuous IV infusion has been used.

Milrinone lactate

infusion solution, in D5W

  • 20mg/100mL
  • 40mg/200mL

injectable solution

  • 1mg/mL
Drugs Generic
Tags

About the Author

postblaze

You may also like these

0